Market Place
Sourcing Support
Cartesian Therapeutics Announces New Employment Inducement Grants
08 Nov 2024 //
GLOBENEWSWIRE
Cartesian Therapeutics Q3 2024 Results & Business Update
07 Nov 2024 //
GLOBENEWSWIRE
Cartesian Therapeutics to Present at ASH 2024 Annual Meeting
05 Nov 2024 //
GLOBENEWSWIRE
Cartesian Presents Ph 2b Results Of Descartes-08 At AANEM Meeting
15 Oct 2024 //
GLOBENEWSWIRE
Cartesian Therapeutics Announces New Employment Inducement Grants
04 Oct 2024 //
GLOBENEWSWIRE
Cartesian Receives FDA Rare Pediatric Disease Designation
09 Sep 2024 //
GLOBENEWSWIRE
Cartesian Therapeutics Announces New Employment Inducement Grant
06 Sep 2024 //
GLOBENEWSWIRE
Cartesian Doses First Patient in Phase 1 mRNA CAR-T Therapy Descartes-15
03 Sep 2024 //
GLOBENEWSWIRE
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
26 Aug 2024 //
GLOBENEWSWIRE
Cartesian Therapeutics Reports Q2 2024 Results And Business Update
08 Aug 2024 //
GLOBENEWSWIRE
Cartesian Therapeutics Announces New Employment Inducement Grants
07 Aug 2024 //
GLOBENEWSWIRE
Cartesian Therapeutics Announces New Employment Inducement Grants
08 Jul 2024 //
GLOBENEWSWIRE
Cartesian Starts Phase 2 Trial Of Descartes-08 For Lupus
04 Jul 2024 //
PHARMABIZ
Cartesian claims phase 2b autoimmune CAR-T win after changing endpoint
03 Jul 2024 //
FIERCE PHAMA
Cartesian Reports Positive Ph 2b Results For Descartes-08 In Myasthenia Gravis
02 Jul 2024 //
GLOBENEWSWIRE
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
02 Jul 2024 //
GLOBENEWSWIRE
Cartesian Therapeutics Doses First Patient In Descartes-08 SLE Trial
02 Jul 2024 //
GLOBENEWSWIRE
Cartesian Therapeutics Appoints Kemal Malik To Board Of Directors
02 Jul 2024 //
GLOBENEWSWIRE
Cartesian Therapeutics Announces New Employment Inducement Grant
06 Jun 2024 //
GLOBENEWSWIRE
Cartesian Gets RMAT For Descartes-08 In Myasthenia Gravis
22 May 2024 //
GLOBENEWSWIRE
Cartesian At HC Wainwright BioConnect Conference
13 May 2024 //
GLOBENEWSWIRE
Cartesian Q1 2024 Results, Business Update
08 May 2024 //
GLOBENEWSWIRE
Cartesian Therapeutics Announces New Employment Inducement Grants
06 May 2024 //
BUSINESSWIRE
Cartesian`s Announces New Employment Inducement Grants
06 May 2024 //
PRESS RELEASE
Cartesian to Present at ASGCT 27th Annual Meeting
22 Apr 2024 //
PRESS RELEASE
Cartesian ` Rare Disease Candidate Shows Long Benefit Over Argenx`s Vyvgart
10 Apr 2024 //
MARKETBUSINESSINSIDER
Cartesian Therapeutics Announces New Employment Inducement Grants
04 Apr 2024 //
BUSINESSWIRE
Cartesian Therapeutics to Participate in the 23rd Annual NVH Conference
04 Apr 2024 //
BUSINESSWIRE
Cartesian Announces Approval of Conversion of Series A Convertible Stock
28 Mar 2024 //
GLOBENEWSWIRE
Cartesian Therapeutics Reports Full Year 2023 Financial Results
07 Mar 2024 //
GLOBENEWSWIRE
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
06 Mar 2024 //
GLOBENEWSWIRE
Cartesian Therapeutics Establishes New Corporate Headquarters
05 Mar 2024 //
GLOBENEWSWIRE
Cartesian Therapeutics Announces New Employment Inducement Grant
05 Mar 2024 //
GLOBENEWSWIRE
Cartesian Therapeutics Announces New Employment Inducement Grants
05 Feb 2024 //
GLOBENEWSWIRE
Cartesian Announces Positive Data from Phase 2a Study of Descartes-08
08 Jan 2024 //
GLOBENEWSWIRE
Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities
08 Jan 2024 //
GLOBENEWSWIRE
Selecta fuses with Cartesian in reverse merger
13 Nov 2023 //
FIERCE BIOTECH
Cartesian announces successful trial of RNA cell therapy in autoimmunity
23 Jun 2023 //
PHARMAFILE
Cartesian Therapeutics Announces Landmark Study in The Lancet Neurology
22 Jun 2023 //
BUSINESSWIRE
CAR-T cell therapy for myasthenia gravis shows promise in study by Cartesian
22 Jun 2023 //
ENDPTS
Cartesian Doses Patient with First Allogeneic RNA Cell Therapy
25 Jan 2022 //
PRNEWSWIRE
Cartesian Therapeutics Adds Five Internationally Recognized Experts
14 Dec 2021 //
PRNEWSWIRE
Cartesian Wins Fourth NIH Grant for Clinical Trials of RNA Cell Therapies
04 May 2021 //
PRNEWSWIRE
Cartesian Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy
22 Feb 2021 //
PRNEWSWIRE
